Tag: Secukinumab

Over 60% of patients taking some of the latest biologic medications are expected to see a complete clearance of psoriasis plaques within three to four months [1.2.6]. Understanding **how quickly do biologics work for psoriasis** involves looking at the specific drug, its mechanism, and individual patient factors.

Developed by the Swiss pharmaceutical company Novartis, the groundbreaking biologic Cosentyx, or **secukinumab**, was the first interleukin-17A (IL-17A) inhibitor to receive FDA approval, marking a significant advancement for treating autoimmune and inflammatory diseases. Its development was a long process involving extensive research into inflammatory pathways.

As of mid-2025, the monthly list price for Cosentyx (secukinumab) can be around $7,936 for a self-injection package, making the cash price without insurance prohibitively expensive for most patients. While this price is exceptionally high, there are several viable avenues for reducing the cost and making Cosentyx accessible, even without insurance coverage.

Cosentyx (secukinumab), first FDA-approved in 2015 for moderate-to-severe plaque psoriasis, has since been approved for several other conditions including psoriatic arthritis and ankylosing spondylitis. Despite its proven efficacy, many patients and healthcare providers may need to find out **what is comparable to Cosentyx** for a variety of reasons, including effectiveness, side effects, or drug class limitations.

Over 80 million people worldwide live with autoimmune diseases, driving the development of targeted therapies. A common question patients have is, 'Is Cosentyx a JAK inhibitor?' The answer is no; they belong to entirely different drug classes with distinct mechanisms. [1.6.1, 1.10.3]

Approximately 125 million people worldwide suffer from psoriasis, and many may wonder, 'is Cosentyx or Taltz better?'. Both are powerful biologic medications that treat similar autoimmune conditions by blocking the inflammatory protein interleukin-17A, but they have key differences in efficacy, dosing, and approved uses.

In clinical trials, many people taking Cosentyx for plaque psoriasis have shown significant improvement. The generic name for Cosentyx is **secukinumab**, and it is important to understand what this means for patients with autoimmune conditions.